Cargando…

Management of enterococcal central line-associated bloodstream infections in patients with cancer

OBJECTIVE: Enterococcus species are the third most common organisms causing central line-associated bloodstream infections (CLABSIs). The management of enterococcal CLABSI, including the need for and timing of catheter removal, is not well defined. We therefore conducted this study to determine the...

Descripción completa

Detalles Bibliográficos
Autores principales: Awadh, Hesham, Chaftari, Anne-Marie, Khalil, Melissa, Fares, Johny, Jiang, Ying, Deeba, Rita, Ali, Shahnoor, Hachem, Ray, Raad, Issam I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256598/
https://www.ncbi.nlm.nih.gov/pubmed/34225651
http://dx.doi.org/10.1186/s12879-021-06328-9
_version_ 1783718130647826432
author Awadh, Hesham
Chaftari, Anne-Marie
Khalil, Melissa
Fares, Johny
Jiang, Ying
Deeba, Rita
Ali, Shahnoor
Hachem, Ray
Raad, Issam I.
author_facet Awadh, Hesham
Chaftari, Anne-Marie
Khalil, Melissa
Fares, Johny
Jiang, Ying
Deeba, Rita
Ali, Shahnoor
Hachem, Ray
Raad, Issam I.
author_sort Awadh, Hesham
collection PubMed
description OBJECTIVE: Enterococcus species are the third most common organisms causing central line-associated bloodstream infections (CLABSIs). The management of enterococcal CLABSI, including the need for and timing of catheter removal, is not well defined. We therefore conducted this study to determine the optimal management of enterococcal CLABSI in cancer patients. METHODS: We reviewed data for 542 patients diagnosed with Enterococcus bacteremia between September 2011 to December 2018. After excluding patients without an indwelling central venous catheter (CVC), polymicrobial bacteremia or with CVC placement less than 48 h from bacteremia onset we classified the remaining 397 patients into 3 groups: Group 1 (G1) consisted of patients with CLABSI with mucosal barrier injury (MBI), Group 2 (G2) included patients with either catheter-related bloodstream infection (CRBSI) as defined in 2009 Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection by the Infectious Diseases Society of America (IDSA) or CLABSI without MBI, and Group 3 (G3) consisted of patients who did not meet the CDC criteria for CLABSI. The impact of early (< 3 days after bacteremia onset) and late (3–7 days) CVC removal was compared. The composite primary outcome included absence of microbiologic recurrence, 90-day infection-related mortality, and 90-day infection-related complications. RESULTS: Among patients in G2, CVC removal within 3 days of bacteremia onset was associated with a trend towards a better overall outcome than those whose CVCs were removed later between days 3 to 7 (success rate 88% vs 63%). However, those who had CVCs retained beyond 7 days had a similar successful outcome than those who had CVC removal < 3 days (92% vs. 88%). In G1, catheter retention (removal > 7 days) was associated with a better success rates than catheter removal between 3 and 7 days (93% vs. 67%, p = 0.003). In non-CLABSI cases (G3), CVC retention (withdrawal > 7 days) was significantly associated with a higher success rates compared to early CVC removal (< 3 days) (90% vs. 64%, p = 0.006). CONCLUSION: Catheter management in patients with enterococcal bacteremia is challenging. When CVC removal is clinically indicated in patients with enterococcal CLABSI, earlier removal in less than 3 days may be associated with better outcomes. Based on our data, we cannot make firm conclusions about whether earlier removal (< 3 days) could be associated with better outcomes in patients with Enterococcal CLABSI whose CVC withdrawal is clinically indicated. In contrast, it seemed that catheter retention was associated to higher success outcome rates. Therefore, future studies are needed to clearly assess this aspect.
format Online
Article
Text
id pubmed-8256598
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82565982021-07-06 Management of enterococcal central line-associated bloodstream infections in patients with cancer Awadh, Hesham Chaftari, Anne-Marie Khalil, Melissa Fares, Johny Jiang, Ying Deeba, Rita Ali, Shahnoor Hachem, Ray Raad, Issam I. BMC Infect Dis Research OBJECTIVE: Enterococcus species are the third most common organisms causing central line-associated bloodstream infections (CLABSIs). The management of enterococcal CLABSI, including the need for and timing of catheter removal, is not well defined. We therefore conducted this study to determine the optimal management of enterococcal CLABSI in cancer patients. METHODS: We reviewed data for 542 patients diagnosed with Enterococcus bacteremia between September 2011 to December 2018. After excluding patients without an indwelling central venous catheter (CVC), polymicrobial bacteremia or with CVC placement less than 48 h from bacteremia onset we classified the remaining 397 patients into 3 groups: Group 1 (G1) consisted of patients with CLABSI with mucosal barrier injury (MBI), Group 2 (G2) included patients with either catheter-related bloodstream infection (CRBSI) as defined in 2009 Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection by the Infectious Diseases Society of America (IDSA) or CLABSI without MBI, and Group 3 (G3) consisted of patients who did not meet the CDC criteria for CLABSI. The impact of early (< 3 days after bacteremia onset) and late (3–7 days) CVC removal was compared. The composite primary outcome included absence of microbiologic recurrence, 90-day infection-related mortality, and 90-day infection-related complications. RESULTS: Among patients in G2, CVC removal within 3 days of bacteremia onset was associated with a trend towards a better overall outcome than those whose CVCs were removed later between days 3 to 7 (success rate 88% vs 63%). However, those who had CVCs retained beyond 7 days had a similar successful outcome than those who had CVC removal < 3 days (92% vs. 88%). In G1, catheter retention (removal > 7 days) was associated with a better success rates than catheter removal between 3 and 7 days (93% vs. 67%, p = 0.003). In non-CLABSI cases (G3), CVC retention (withdrawal > 7 days) was significantly associated with a higher success rates compared to early CVC removal (< 3 days) (90% vs. 64%, p = 0.006). CONCLUSION: Catheter management in patients with enterococcal bacteremia is challenging. When CVC removal is clinically indicated in patients with enterococcal CLABSI, earlier removal in less than 3 days may be associated with better outcomes. Based on our data, we cannot make firm conclusions about whether earlier removal (< 3 days) could be associated with better outcomes in patients with Enterococcal CLABSI whose CVC withdrawal is clinically indicated. In contrast, it seemed that catheter retention was associated to higher success outcome rates. Therefore, future studies are needed to clearly assess this aspect. BioMed Central 2021-07-05 /pmc/articles/PMC8256598/ /pubmed/34225651 http://dx.doi.org/10.1186/s12879-021-06328-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Awadh, Hesham
Chaftari, Anne-Marie
Khalil, Melissa
Fares, Johny
Jiang, Ying
Deeba, Rita
Ali, Shahnoor
Hachem, Ray
Raad, Issam I.
Management of enterococcal central line-associated bloodstream infections in patients with cancer
title Management of enterococcal central line-associated bloodstream infections in patients with cancer
title_full Management of enterococcal central line-associated bloodstream infections in patients with cancer
title_fullStr Management of enterococcal central line-associated bloodstream infections in patients with cancer
title_full_unstemmed Management of enterococcal central line-associated bloodstream infections in patients with cancer
title_short Management of enterococcal central line-associated bloodstream infections in patients with cancer
title_sort management of enterococcal central line-associated bloodstream infections in patients with cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256598/
https://www.ncbi.nlm.nih.gov/pubmed/34225651
http://dx.doi.org/10.1186/s12879-021-06328-9
work_keys_str_mv AT awadhhesham managementofenterococcalcentrallineassociatedbloodstreaminfectionsinpatientswithcancer
AT chaftariannemarie managementofenterococcalcentrallineassociatedbloodstreaminfectionsinpatientswithcancer
AT khalilmelissa managementofenterococcalcentrallineassociatedbloodstreaminfectionsinpatientswithcancer
AT faresjohny managementofenterococcalcentrallineassociatedbloodstreaminfectionsinpatientswithcancer
AT jiangying managementofenterococcalcentrallineassociatedbloodstreaminfectionsinpatientswithcancer
AT deebarita managementofenterococcalcentrallineassociatedbloodstreaminfectionsinpatientswithcancer
AT alishahnoor managementofenterococcalcentrallineassociatedbloodstreaminfectionsinpatientswithcancer
AT hachemray managementofenterococcalcentrallineassociatedbloodstreaminfectionsinpatientswithcancer
AT raadissami managementofenterococcalcentrallineassociatedbloodstreaminfectionsinpatientswithcancer